Duan Bo-Shi, Xie Long-Fei, Wang Yue
Department of Internal Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, P.R. China.
Department of Biology, University of California, Berkeley, CA, U.S.A.
Cancer Genomics Proteomics. 2017 Jul-Aug;14(4):277-284. doi: 10.21873/cgp.20038.
BACKGROUND/AIM: T-cadherin is a tumor suppressor gene, its predictive value in colorectal cancer (CRC) still remains controversial. In this study, we aimed to evaluate the association between T-cadherin promoter methylation and CRC by performing a meta-analysis.
The relevant literature was searched using the PubMed, Cochrane Library, Web of Science and Google Scholar databases for articles published until December 2016. The effect sizes were estimated by measuring an odds ratio (OR) with a 95% confidence interval (CI). Sensitivity analysis was performed to examine the heterogeneity and funnel plots were constructed to evaluate publication bias.
Nine studies, including 488 samples were included in this meta-analysis. The pooled OR of T-cadherin promoter methylation in cancer tissues was 16.73 (95%CI=6.24-44.87), 19.48 (95%CI=5.64-67.31) and 2.23 (95%CI=1.05-4.75) compared to normal tissues, adjacent tissues and premalignant tissues, respectively. The relationship between T-cadherin promoter methylation and clinicopathological features were also analyzed. However, a significant association was not observed between T-cadherin promoter methylation status and gender, tumor stage, and lymph node status (p>0.05).
The methylation status of T-cadherin promoter was strongly associated with CRC risk. However, T-cadherin promoter methylation may have a limited prognostic value for CRC patients.
背景/目的：T-钙黏蛋白是一种肿瘤抑制基因，其在结直肠癌（CRC）中的预测价值仍存在争议。在本研究中，我们旨在通过进行荟萃分析来评估T-钙黏蛋白启动子甲基化与CRC之间的关联。
使用PubMed、Cochrane图书馆、科学网和谷歌学术数据库检索截至2016年12月发表的相关文献。通过测量比值比（OR）及其95%置信区间（CI）来估计效应大小。进行敏感性分析以检验异质性，并构建漏斗图以评估发表偏倚。
本荟萃分析纳入了9项研究，共488个样本。与正常组织、癌旁组织和癌前组织相比，癌组织中T-钙黏蛋白启动子甲基化的合并OR分别为16.73（95%CI=6.24-44.87）、19.48（95%CI=5.64-67.31）和2.23（95%CI=1.05-4.75）。还分析了T-钙黏蛋白启动子甲基化与临床病理特征之间的关系。然而，未观察到T-钙黏蛋白启动子甲基化状态与性别、肿瘤分期及淋巴结状态之间存在显著关联（p>0.05）。
T-钙黏蛋白启动子的甲基化状态与CRC风险密切相关。然而，T-钙黏蛋白启动子甲基化对CRC患者的预后价值可能有限。
